Found: 98
Select item for more details and to access through your institution.
An atypical ear nodule.
- Published in:
- Indian Journal of Dermatology, Venereology & Leprology, 2022, v. 88, n. 4, p. 564, doi. 10.25259/IJDVL_555_20
- By:
- Publication type:
- Article
Tumor necrosis factor-alpha presence in post mortem cardiac tissue of psoriatic patients.
- Published in:
- 2024
- By:
- Publication type:
- Letter
A case of erythrodermic psoriasis rapidly and successfully treated with Bimekizumab.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
A case of linear psoriasis in a young patient with Down syndrome and review of the literature.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
Teledermatology in the management of hidradenitis suppurativa: Should we improve this service?
- Published in:
- Journal of Cosmetic Dermatology, 2023, v. 22, n. 2, p. 677, doi. 10.1111/jocd.15292
- By:
- Publication type:
- Article
MRI in Pregnancy and Precision Medicine: A Review from Literature.
- Published in:
- Journal of Personalized Medicine, 2022, v. 12, n. 1, p. 9, doi. 10.3390/jpm12010009
- By:
- Publication type:
- Article
Ocular Manifestations in Psoriasis Screening (OcMaPS) Questionnaire: A Useful Tool to Reveal Misdiagnosed Ocular Involvement in Psoriasis.
- Published in:
- Journal of Clinical Medicine, 2021, v. 10, n. 5, p. 1031, doi. 10.3390/jcm10051031
- By:
- Publication type:
- Article
Cutaneous adverse reaction following COVID‐19 vaccination: Report from a southern Italian referral centre. Comment on "cutaneous adverse reactions following the Pfizer/BioNTech COVID‐19 vaccine" by Luo et al.
- Published in:
- Australasian Journal of Dermatology, 2023, v. 64, n. 1, p. e103, doi. 10.1111/ajd.13984
- By:
- Publication type:
- Article
A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab [Corrigendum].
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study.
- Published in:
- Clinical, Cosmetic & Investigational Dermatology, 2024, v. 17, p. 1037, doi. 10.2147/CCID.S464326
- By:
- Publication type:
- Article
Secukinumab for Severe Hidradenitis Suppurativa in a Patient on Haemodialysis: Efficacy and Safety on 300 mg Every 2 Weeks Administration – A Case Report.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
The Past, the Present and the Future of Teledermatology: A Narrative Review.
- Published in:
- Clinical, Cosmetic & Investigational Dermatology, 2024, v. 17, p. 717, doi. 10.2147/CCID.S462799
- By:
- Publication type:
- Article
L-Lysine as an Alternative Treatment for Pityriasis Rosea (PR) [Response to Letter].
- Published in:
- 2024
- By:
- Publication type:
- Letter to the Editor
A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
JAK Inhibitors in Psoriatic Disease.
- Published in:
- Clinical, Cosmetic & Investigational Dermatology, 2023, v. 16, p. 3129, doi. 10.2147/CCID.S433367
- By:
- Publication type:
- Article
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data.
- Published in:
- Clinical, Cosmetic & Investigational Dermatology, 2023, v. 16, p. 2525, doi. 10.2147/CCID.S418748
- By:
- Publication type:
- Article
Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas.
- Published in:
- Clinical, Cosmetic & Investigational Dermatology, 2023, v. 16, p. 2637, doi. 10.2147/CCID.S423234
- By:
- Publication type:
- Article
Biologics for the Management of Erythrodermic Psoriasis: An Updated Review.
- Published in:
- Clinical, Cosmetic & Investigational Dermatology, 2023, v. 16, p. 2045, doi. 10.2147/CCID.S407813
- By:
- Publication type:
- Article
Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?
- Published in:
- Clinical, Cosmetic & Investigational Dermatology, 2023, v. 16, p. 1677, doi. 10.2147/CCID.S407812
- By:
- Publication type:
- Article
Injections Site Reactions and Biologics for Psoriasis: A Questionnaire Based Real Life Study.
- Published in:
- Clinical, Cosmetic & Investigational Dermatology, 2023, v. 16, p. 553, doi. 10.2147/CCID.S400679
- By:
- Publication type:
- Article
Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study.
- Published in:
- Clinical, Cosmetic & Investigational Dermatology, 2023, v. 16, p. 529, doi. 10.2147/CCID.S402183
- By:
- Publication type:
- Article
Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection.
- Published in:
- Clinical, Cosmetic & Investigational Dermatology, 2023, v. 16, p. 369, doi. 10.2147/CCID.S403294
- By:
- Publication type:
- Article
The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review.
- Published in:
- Clinical, Cosmetic & Investigational Dermatology, 2022, v. 15, p. 2785, doi. 10.2147/CCID.S377029
- By:
- Publication type:
- Article
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence.
- Published in:
- Clinical, Cosmetic & Investigational Dermatology, 2022, v. 15, p. 1649, doi. 10.2147/CCID.S364640
- By:
- Publication type:
- Article
Strategies to Improve Outcomes of Bullous Pemphigoid: A Comprehensive Review of Clinical Presentations, Diagnosis, and Patients' Assessment.
- Published in:
- Clinical, Cosmetic & Investigational Dermatology, 2022, v. 15, p. 661, doi. 10.2147/CCID.S267573
- By:
- Publication type:
- Article
Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data.
- Published in:
- Immunologic Research, 2023, v. 71, n. 3, p. 328, doi. 10.1007/s12026-022-09356-y
- By:
- Publication type:
- Article
Skin Needling in Combination with Antimicrobial Peptides for the Treatment of Keloids: A Novel Perspective Proposal and Approach for Skin Scars.
- Published in:
- 2020
- By:
- Publication type:
- Letter
Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life Study.
- Published in:
- Journal of Clinical Medicine, 2024, v. 13, n. 9, p. 2691, doi. 10.3390/jcm13092691
- By:
- Publication type:
- Article
Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 9, p. 3233, doi. 10.3390/jcm12093233
- By:
- Publication type:
- Article
The Use of JAK/STAT Inhibitors in Chronic Inflammatory Disorders.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 8, p. 2865, doi. 10.3390/jcm12082865
- By:
- Publication type:
- Article
Persistent candidiasis infection during anti‐IL‐17 treatment for plaque psoriasis requiring biologic discontinuation: a case series and literature review.
- Published in:
- International Journal of Dermatology, 2023, v. 62, n. 3, p. e135, doi. 10.1111/ijd.16429
- By:
- Publication type:
- Article
Reply to: "Usage and perceptions of teledermatology in 2021: a survey of dermatologists" by Ahmad et al.
- Published in:
- International Journal of Dermatology, 2023, v. 62, n. 2, p. e80, doi. 10.1111/ijd.16326
- By:
- Publication type:
- Article
Reply to "Where are the older adults? Age distribution of nail psoriasis‐randomized clinical trials' participants: a systematic review" by Ricardo JW et al.
- Published in:
- International Journal of Dermatology, 2022, v. 61, n. 10, p. e364, doi. 10.1111/ijd.16379
- By:
- Publication type:
- Article
QuantiFERON TB‐gold conversion rate among psoriasis patients under biologics: a 9‐year retrospective study.
- Published in:
- International Journal of Dermatology, 2021, v. 60, n. 3, p. 352, doi. 10.1111/ijd.15217
- By:
- Publication type:
- Article
Secukinumab: a potential safe option in psoriasis patients affected by multiple sclerosis?
- Published in:
- International Journal of Dermatology, 2020, v. 59, n. 8, p. e308, doi. 10.1111/ijd.14902
- By:
- Publication type:
- Article
Cutaneous Squamous Cell Carcinoma: From Diagnosis to Follow-Up.
- Published in:
- Cancers, 2024, v. 16, n. 17, p. 2960, doi. 10.3390/cancers16172960
- By:
- Publication type:
- Article
Advanced Squamous Cell Carcinoma Developed on Chronic Hidradenitis Suppurativa, Successfully Treated with Cemiplimab: A Case Report.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
A Case of Recalcitrant Circinate Generalized (Lapière) Psoriasis Successfully Treated with Risankizumab.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
Low dose oral corticosteroids, microneedling, and topical 5‐fluorouracil: A novel treatment for recalcitrant pediatric vitiligo.
- Published in:
- Pediatric Dermatology, 2021, v. 38, n. 1, p. 322, doi. 10.1111/pde.14443
- By:
- Publication type:
- Article
Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature.
- Published in:
- Psoriasis: Targets & Therapy, 2023, v. 13, p. 19, doi. 10.2147/PTT.S407647
- By:
- Publication type:
- Article
Towards Personalized Medicine in Psoriasis: Current Progress.
- Published in:
- Psoriasis: Targets & Therapy, 2022, v. 12, p. 231, doi. 10.2147/PTT.S328460
- By:
- Publication type:
- Article
Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study.
- Published in:
- Psoriasis: Targets & Therapy, 2022, v. 12, p. 205, doi. 10.2147/PTT.S372262
- By:
- Publication type:
- Article
Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge.
- Published in:
- Psoriasis: Targets & Therapy, 2022, v. 12, p. 127, doi. 10.2147/PTT.S367744
- By:
- Publication type:
- Article
Management Strategies for Pediatric Moderate-to-Severe Plaque Psoriasis: Spotlight on Biologics.
- Published in:
- Pediatric Health, Medicine & Therapeutics, 2023, v. 14, p. 435, doi. 10.2147/PHMT.S389108
- By:
- Publication type:
- Article
The Impact of COVID-19 Vaccination on Inflammatory Skin Disorders and Other Cutaneous Diseases: A Review of the Published Literature.
- Published in:
- Viruses (1999-4915), 2023, v. 15, n. 7, p. 1423, doi. 10.3390/v15071423
- By:
- Publication type:
- Article
Tildrakizumab for the treatment of moderate to severe psoriasis: Results from a single center preliminary real‐life study.
- Published in:
- Dermatologic Therapy, 2022, v. 35, n. 12, p. 1, doi. 10.1111/dth.15941
- By:
- Publication type:
- Article
Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single‐center retrospective study in a real‐life setting.
- Published in:
- Dermatologic Therapy, 2022, v. 35, n. 9, p. 1, doi. 10.1111/dth.15667
- By:
- Publication type:
- Article
Risankizumab treatment in psoriasis patients who failed anti‐IL17: A 52‐week real‐life study.
- Published in:
- Dermatologic Therapy, 2022, v. 35, n. 7, p. 1, doi. 10.1111/dth.15524
- By:
- Publication type:
- Article
New‐onset lichen planus arising after COVID‐19 vaccination.
- Published in:
- Dermatologic Therapy, 2022, v. 35, n. 5, p. 1, doi. 10.1111/dth.15374
- By:
- Publication type:
- Article